{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:17:17Z","timestamp":1789906637954,"version":"4.0.1"},"reference-count":20,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,3,2]]},"abstract":"<jats:p>Background: Although established therapies are effective in most patients with generalized myasthenia gravis (gMG), some patients do not respond or they experience intolerable adverse events, highlighting the need for better tolerated, targeted therapies for treatment-refractory gMG. Objective: To describe real-world experience with eculizumab in patients with treatment-refractory acetylcholine receptor antibody-positive (AChR+) gMG. Methods: Retrospective chart review of 15 patients with treatment-refractory AChR+ gMG treated for 12 months with eculizumab (900\u200amg\/week for 4 weeks then 1200\u200amg every 2 weeks). Outcome measures were Myasthenia Gravis\u2013Activities of Daily Living (MG-ADL) scores, number of exacerbations, single-breath count test (SBCT) score, medication changes, selected Quantitative Myasthenia Gravis (QMG) evaluations, and adverse events. Data collected at 3-monthly intervals for 12 months before and after eculizumab initiation were analyzed. Results: Clinically meaningful reductions in total MG-ADL scores were observed at 3 months following eculizumab initiation and maintained up to 12 months in all patients. After 12 months\u2019 eculizumab treatment, there was a significant reduction in the number of acute exacerbations; mean (SD) SBCT score improved from 28.13 (0.33) to 50.26 (2.86); all patients achieved a \u2018none\u2019 or \u2018mild\u2019 rating for QMG evaluations; all patients reduced their daily prednisone dose; and nine patients had discontinued pyridostigmine. At the end of treatment, intravenous immunoglobulin was discontinued in all six patients receiving this therapy at eculizumab initiation. Eculizumab was well tolerated. Conclusions: This real-world study demonstrated improvement in outcome measures and decreased concomitant drug requirement within 12 months of eculizumab initiation in patients with treatment-refractory AChR+ gMG.<\/jats:p>","DOI":"10.3233\/jnd-200584","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T23:41:26Z","timestamp":1607470886000},"page":"287-294","source":"Crossref","is-referenced-by-count":35,"title":["Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis"],"prefix":"10.1177","volume":"8","author":[{"given":"Nakul","family":"Katyal","sequence":"first","affiliation":[{"name":"University of Missouri Health Care, Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Narula","sequence":"additional","affiliation":[{"name":"University of Missouri Health Care, Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"University of Missouri Health Care, Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JND-200584_ref1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JND-200584_ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"10.3233\/JND-200584_ref3","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JND-200584_ref4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s00415-009-5318-9","article-title":"Unsatisfactory outcomes in myasthenia gravis: influence by care providers","volume":"257","author":"Dunand","year":"2010","journal-title":"J Neurol"},{"issue":"5-6","key":"10.3233\/JND-200584_ref5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"issue":"17-18","key":"10.3233\/JND-200584_ref6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/s0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"issue":"1","key":"10.3233\/JND-200584_ref7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizu-mab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.3233\/JND-200584_ref8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.3233\/JND-200584_ref12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"11","key":"10.3233\/JND-200584_ref13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized doubleblind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"issue":"4","key":"10.3233\/JND-200584_ref14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"J Clin Neuromuscul Dis"},{"issue":"1","key":"10.3233\/JND-200584_ref15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mus.24929","article-title":"Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis","volume":"53","author":"Elsheikh","year":"2016","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.3233\/JND-200584_ref16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.3233\/JND-200584_ref17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.12659\/AJCR.916424","article-title":"Safety of an abbreviated transition period when switching from intravenous immunoglobulin to eculizumab in patients with treatment-refractory myasthenia gravis: a case series","volume":"20","author":"Levine","year":"2019","journal-title":"Am J Case Rep"},{"issue":"3","key":"10.3233\/JND-200584_ref18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.3233\/JND-200584_ref19","first-page":"106","article-title":"Efficacy of eculizumab on myasthenia gravis-activities of daily living and its respiratory, bulbar, limb and ocular domains in patients with ACHR+ refractory generalized myasthenia gravis","volume":"56","author":"Howard","year":"2017","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.3233\/JND-200584_ref20","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"issue":"2","key":"10.3233\/JND-200584_ref21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"10.3233\/JND-200584_ref22","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.3233\/JND-200584_ref23","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-200584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:36Z","timestamp":1777506576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-200584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":20,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jnd-200584","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}